TICKERNERD
Menu
AURAAURAHealthcare · Biotechnology

AURA Stock Forecast: Aura Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.00
+0.07% on the day

The 6 Wall Street analysts covering Aura Biosciences, Inc. hold a median 12-month price target of $15 — +114.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$724.9M
Ticker Nerd rank
39 / 100
Median analyst target
$15
Analysts covering
6
Revenue$0.0
Operating income−$48.1M
Net income−$45.6M
Free cash flow−$32.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−13.0%
YTD
+28.3%
1Y
+5.3%
From 52W high
−21.4%
From 52W low
+40.7%
$4.97
$8.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aura Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
64
Accruals
62
Value
60
Momentum
51
Quality
50
Size
49
Growth
43
Issuance
37
Revisions
30

Volatility (64): The share price has been relatively steady.

Revisions (30): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26AURAHigh $23Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $12Median $15High $23

The green dot is the last close — the median target sits +114.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.MaintainsBuy$24 → $18
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
29 Apr 2026HC Wainwright & Co.MaintainsBuy$22 → $24
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025Evercore ISI GroupReinstatesOutperform$13
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
28 May 2025HC Wainwright & Co.AssumesBuy$22
23 May 2025JMP SecuritiesReiteratesMarket Outperform—
26 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
26 Mar 2025JMP SecuritiesMaintainsMarket Outperform—
25 Mar 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024JMP SecuritiesMaintainsMarket Outperform—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024BTIGMaintainsBuy—
18 Oct 2024HC Wainwright & Co.MaintainsBuy—
18 Oct 2024ScotiabankMaintainsSector Outperform—
13 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 Sept 2024JMP SecuritiesMaintainsMarket Outperform—
28 Aug 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Aura Biosciences, Inc. returned +5.3% against +17.5% for the S&P 500, dividends included.

AURA vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Oct 25Jan 26Apr 26Jul 26AURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Aura Biosciences, Inc. (AURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.0×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
2.3×

Cheaper than 41% of US stocks

EV / EBITDA
−3.0×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−53.5%

Higher than 20% of US stocks

Return on assets
−31.2%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aura Biosciences, Inc. (AURA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aura Biosciences, Inc. has a market value of $724.9M and an enterprise value of $417.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$131.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$103.4M.

  • Shares outstanding: 103.4M.

  • Trailing P/E: −4.0×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aura Biosciences, Inc. employs 113 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

AURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AURAAura Biosciences, Inc.$724.9M
39
ACHVAchieve Life Sciences, Inc.$724.8M
28
FDMT4D Molecular Therapeutics, Inc.$727.6M
52
CBIOCrescent Biopharma, Inc.$717.4M
54
CTMXCytomX Therapeutics, Inc.$711.2M
47
MNPRMonopar Therapeutics, Inc.$736.8M
57
ZVRAZevra Therapeutics, Inc.$705.1M
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aura Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AURA news & analysis

Aura Biosciences to Participate in Upcoming Investor Conference

GlobeNewsWire · 2 Sept 2026neutral

Aura Biosciences announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026. The announcement was made via GlobeNewsWire on September 2, 2026.

Why it matters — AURA watchers may be interested as the CEO's participation at a major investor conference offers a platform for the company to present its clinical-stage ocular cancer therapy to the investment community.

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 1 Sept 2026neutral

Aura Biosciences announced on September 1, 2026 that it granted inducement equity awards to three newly appointed executives — Erica Kratz (Chief Regulatory and Quality Officer), Susan Abu-Absi (Chief Operating Officer), and Julie Person (Chief People Officer). The awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — Aura watchers would care because this reflects the addition of three new C-suite leaders and associated equity compensation, which is standard corporate governance news for the company.

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Seeking Alpha · 12 Aug 2026positive

Aura Biosciences is advancing Bel-sar for early choroidal melanoma, with the Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027. Phase 2 data showed 80% tumor control and a strong safety profile, and the company recently completed a C-suite overhaul and a $299 million capital raise, with funding expected to last into 2029.

Why it matters — AURA watchers would care because the streamlined management and extended cash runway position the company to reach its pivotal Phase 3 readout for Bel-sar, a potential first-in-class treatment in a field with significant unmet need.

FAQ

Frequently asked questions about AURA stock

What is the AURA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Aura Biosciences, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AURA stock a buy right now?

Of the 6 analysts covering Aura Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aura Biosciences, Inc. 39 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AURA?

As at 11 Sept 2026, Aura Biosciences, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (64 of 100).

Will AURA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +114.4% from the last close, and Ticker Nerd's factor model ranks Aura Biosciences, Inc. 39 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AURA stock forecast for 2030?

No analyst covering Aura Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $23 over the next 12 months.

How has AURA stock performed over the past year?

Aura Biosciences, Inc. returned +5.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aura Biosciences, Inc. do?

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers.

What is the latest news on AURA?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Aura Biosciences to Participate in Upcoming Investor Conference". Aura Biosciences announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026. The announcement was made via GlobeNewsWire on September 2, 2026.

Company

About Aura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.

CEO Ms. Natalie C. Holles · 113 employees · United States · https://www.aurabiosciences.com